Hispanic Broadcasting

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 229 in Hispanic Broadcasting

  1. Hospira, Inc. Announces Voluntary Worldwide Recall of 10 Lots of...Read the original story

    Tuesday Dec 23 | BioSpace

    Hospira, Inc. Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities Hospira Announces Voluntary Worldwide Recall of 10 Lots of Mitoxantrone Due to Confirmed Subpotency and Out-Of-Specification Impurities FOR IMMEDIATE RELEASE December 23, 2014 LAKE FOREST, Ill. Hospira, Inc. , announced today it has initiated a voluntary recall of 10 lots, identified below, of MitoXANTRONE , due to confirmed subpotency and elevated impurity levels.

    Comment?

  2. Select to View Firm Press ReleaseRead the original story

    Tuesday Dec 23 | US Food and Drug Administration

    FOR IMMEDIATE RELEASE December 23, 2014 LAKE FOREST, Ill. Hospira, Inc. , announced today it has initiated a voluntary recall of 10 lots, identified below, of MitoXANTRONE , due to confirmed subpotency and elevated impurity levels.

    Comment?

  3. Hospira Foundation Announces The Leukemia & Lymphoma Society As...Read the original story

    Sunday Dec 21 | BioSpace

    LLS was one of 10 recipients of the initial $10,000 grants for 2, which then participated in a video contest voted on by the public to determine the recipient of the additional from the Hospira Foundation for its national Patient Travel Assistance Program, which assists patients around the country with treatment-related transportation and lodging financial challenges. "We were thrilled to receive the grant from the Hospira Foundation for this program as it's so important to patients," said , Ph.D., president and chief executive officer, The Leukemia & Lymphoma Society.

    Comment?

  4. Hospira, Inc. To Present At The 33rd Annual Healthcare Conference Jan. 14, 2015Read the original story

    Sunday Dec 21 | BioSpace

    It will be available to all interested parties through a live audiocast accessible via the Investor Relations section of Hospira's website at www.hospirainvestor.com . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast.

    Comment?

  5. Hospira to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan. 14, 2015Read the original story

    Friday Dec 19 | Freshnews

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, today announced that the company will present at the J.P. Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in San Francisco. The presentation is scheduled to begin at 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.

    Comment?

  6. Sandoz and Celltrion Decline the Invitation to Dance:...Read the original story w/Photo

    Thursday Dec 18 | jdsupra.com

    In our previous blog post of November 11, 2014, we noted that Celltrion had filed a declaratory judgment action against Kennedy Trust for Rheumatology Research for invalidity of certain patents covering methods of treating rheumatoid arthritis. Celltrion Healthcare Co.

    Comment?

  7. Family of executed Ohio inmate sues expert witnessRead the original story w/Photo

    Tuesday Dec 16 | The Madison Press

    The state's former expert witness on lethal injection should have known that a condemned inmate would suffer because of a two-drug combo that had never been used before, the inmate's family said in a lawsuit. The lawsuit, expanded from an earlier filing, alleges that Dr. Mark Dershwitz knew inmate Dennis McGuire would suffer during the January execution but helped create the state's new lethal injection policy anyway.

    Comment?

  8. Family of Executed Ohio Inmate Sues Expert WitnessRead the original story w/Photo

    Tuesday Dec 16 | US News & World Report

    The state's former expert witness on lethal injection should have known that a condemned inmate would suffer because of a two-drug combo that had never been used before, the inmate's family said in a lawsuit. The lawsuit, expanded from an earlier filing, alleges that Dr. Mark Dershwitz knew inmate Dennis McGuire would suffer during the January execution but helped create the state's new lethal injection policy anyway.

    Comment?

  9. BioTime Subsidiary ES Cell International and GE Healthcare...Read the original story

    Monday Dec 15 | Freshnews

    BioTime, Inc. today announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare have signed a set of license agreements through which GEHC received rights to ESI's stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening.

    Comment?

  10. Hospira, Inc. - Product Pipeline Review - 2014 - New Market Study PublishedRead the original story

    Saturday Dec 13 | PR-inside.com

    This report provides comprehensive information on the current therapeutic developmental pipeline of Hospira, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

    Comment?

  11. BioTime to Host Investor and Analyst Day on December 15, 2014Read the original story

    Friday Dec 12 | Freshnews

    BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15, 2014 at the Harvard Club of New York City. A live webcast of the presentations will begin at 1:15 pm ET and the webcast will conclude by 4:00 pm ET.

    Comment?

  12. Hargreaves Services plc Given "Corporate" Rating at N+1 SingerRead the original story

    Friday Dec 12 | AmericanBankingNews.com

    's stock had its "corporate" rating restated by equities researchers at N+1 Singer in a research report issued on Friday. Hargreaves Services plc traded down 12.10% on Friday, hitting GBX 606.50.

    Comment?

  13. Danone to Discuss the Fate of Its Medical Nutrition UnitRead the original story w/Photo

    Thursday Dec 11 | TheStreet.com

    The board of French food maker Danone SA meet on Thursday, Dec. 11, to discuss offers for its medical nutrition business after receiving bid proposals that reportedly value the business at more than a 3 billion . Danone's board is yet to decide if it will engage with bidders and may opt to hold onto a unit that is not considered to be core to its operations but is fast growing and highly profitable, a source familiar with the matter said.

    Comment?

  14. Cubist Pharmaceuticals Is Acquired By Merck, Gains Remain For InvestorsRead the original story w/Photo

    Wednesday Dec 10 | Seeking Alpha

    Merck & Co. offered to acquire Cubist Pharmaceuticals for $102 per share or a total of $8.4 billion.

    Comment?

  15. Danone's medical nutrition unit on board agenda Thursday - sourceRead the original story w/Photo

    Wednesday Dec 10 | Vallejo News

    French food group Danone will hold a board meeting on Thursday to discuss whether to keep or sell its medical nutrition business, a person familiar with the matter said. Bloomberg earlier on Wednesday said that Danone's board would consider whether to sell the business to a group led by Germany's Fresnius or to Hospira for more than 3 billion euros .

    Comment?

  16. Cubist's lost court bid weighs on $8.4B deal with MerckRead the original story w/Photo

    Tuesday Dec 9 | Worcester Telegram & Gazette

    Cubist Pharmaceuticals Inc., the Lexington drugmaker being bought by Merck & Co. for $8.4 billion, lost a bid to block Hospira Inc. from offering a generic version of its top-selling Cubicin treatment for flesh-eating infections beyond 2016.

    Comment?

  17. Merck-Cubist deal going aheadRead the original story w/Photo

    Tuesday Dec 9 | Investor's Business Daily

    The companies announced the deal Mon., hours before a federal judge in Del. ruled as invalid 4 of 5 Cubist patents on its antibiotic Cubicin that generic-drug maker had challenged.

    Comment?

  18. Will Merck's Acquisition Of Cubist Add Shareholder Value?Read the original story w/Photo

    Tuesday Dec 9 | Seeking Alpha

    Merck To Buy Antibiotics Maker For $8.4 Billion - Deal rationale for Merck to buy Cubist is to build up antibiotics and hospital acute care portfolio as one of 4 core areas going forwards . Cubist's lead product, Cubicin, is a blockbuster with just over $1 billion total sales and it makes up nearly 90% of Cubist's total revenues.

    Comment?

  19. Investors Applaud Hospira, Walgreens for Support of Principles on...Read the original story

    Tuesday Dec 9 | Sys-Con Media

    The principles, included in the Investor Statement on Board Oversight of Biosimilar Issues , call on boards of directors to provide balanced information to policymakers about biosimilar patient safety issues and to increase transparency around the companies' state and federal lobbying on biosimilars. Biosimilars are safe and less costly alternatives to brand biologic drugs and are used to treat patients with serious illnesses, including cancer, rheumatoid arthritis and multiple sclerosis.

    Comment?

  20. Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals IncRead the original story

    Tuesday Dec 9 | Benzinga

    Hospira Inc. ticked up Tuesday after a federal judge ruled that four patents held by Cubist Pharmaceuticals Inc. are invalid. The ruling on Monday may pave the way for Hospira to launch a genetic version of Cubist's Cubicin antibiotic.

    Comment?